| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.098 | 0.04 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.088 | 0.07 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.087 | 0.09 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.074 | 0.1 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.066 | 0.2 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | -0.056 | 0.3 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.039 | 0.4 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.038 | 0.4 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.036 | 0.4 |